DB:5HB

Stock Analysis Report

Shanghai Haohai Biological Technology

Executive Summary

Shanghai Haohai Biological Technology Co., Ltd.


Snowflake Analysis

High growth potential with excellent balance sheet.

Share Price & News

How has Shanghai Haohai Biological Technology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 5HB's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

5.6%

5HB

3.0%

DE Biotechs

9.1%

DE Market


1 Year Return

-48.1%

5HB

-9.5%

DE Biotechs

-13.1%

DE Market

Return vs Industry: 5HB underperformed the German Biotechs industry which returned -7.4% over the past year.

Return vs Market: 5HB underperformed the German Market which returned -14.2% over the past year.


Shareholder returns

5HBIndustryMarket
7 Day5.6%3.0%9.1%
30 Day-19.8%1.5%-1.0%
90 Day-35.2%-23.9%-20.7%
1 Year-48.1%-48.1%-9.2%-9.5%-10.6%-13.1%
3 Year-19.1%-22.0%17.1%15.9%-10.7%-18.1%
5 Yearn/a-8.7%-11.1%-10.7%-22.8%

Price Volatility Vs. Market

How volatile is Shanghai Haohai Biological Technology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Shanghai Haohai Biological Technology undervalued compared to its fair value and its price relative to the market?

11.79x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 5HB (€3.46) is trading above our estimate of fair value (€2.01)

Significantly Below Fair Value: 5HB is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 5HB is good value based on its PE Ratio (11.9x) compared to the Biotechs industry average (43.1x).

PE vs Market: 5HB is good value based on its PE Ratio (11.9x) compared to the German market (17.1x).


Price to Earnings Growth Ratio

PEG Ratio: 5HB is good value based on its PEG Ratio (0.4x)


Price to Book Ratio

PB vs Industry: 5HB is good value based on its PB Ratio (1.2x) compared to the DE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Shanghai Haohai Biological Technology forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

27.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 5HB's forecast earnings growth (27.3% per year) is above the savings rate (-0.4%).

Earnings vs Market: 5HB's earnings (27.3% per year) are forecast to grow faster than the German market (14.1% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 5HB's revenue (22.8% per year) is forecast to grow faster than the German market (3.9% per year).

High Growth Revenue: 5HB's revenue (22.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 5HB's Return on Equity is forecast to be low in 3 years time (12.9%).


Next Steps

Past Performance

How has Shanghai Haohai Biological Technology performed over the past 5 years?

12.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 5HB has high quality earnings.

Growing Profit Margin: 5HB's current net profit margins (23.1%) are lower than last year (26.8%).


Past Earnings Growth Analysis

Earnings Trend: 5HB's earnings have grown by 12.6% per year over the past 5 years.

Accelerating Growth: 5HB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 5HB had negative earnings growth (-10.6%) over the past year, making it difficult to compare to the Biotechs industry average (14.9%).


Return on Equity

High ROE: 5HB's Return on Equity (9.3%) is considered low.


Next Steps

Financial Health

How is Shanghai Haohai Biological Technology's financial position?


Financial Position Analysis

Short Term Liabilities: 5HB's short term assets (CN¥2.2B) exceed its short term liabilities (CN¥335.2M).

Long Term Liabilities: 5HB's short term assets (CN¥2.2B) exceed its long term liabilities (CN¥156.2M).


Debt to Equity History and Analysis

Debt Level: 5HB's debt to equity ratio (1.1%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 5HB's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: 5HB's debt is well covered by operating cash flow (712.3%).

Interest Coverage: 5HB earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Shanghai Haohai Biological Technology's current dividend yield, its reliability and sustainability?

1.87%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 5HB's dividend (1.84%) is higher than the bottom 25% of dividend payers in the German market (1.63%).

High Dividend: 5HB's dividend (1.84%) is low compared to the top 25% of dividend payers in the German market (4.61%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, 5HB has been paying a dividend for less than 10 years.

Growing Dividend: 5HB's dividend payments have increased, but the company has only paid a dividend for 4 years.


Current Payout to Shareholders

Dividend Coverage: Unable to calculate sustainability of dividends as 5HB has not reported any payouts.


Future Payout to Shareholders

Future Dividend Coverage: 5HB's dividends in 3 years are forecast to be well covered by earnings (30.6% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.4yrs

Average management tenure


CEO

Jianying Wu (55yo)

9.75s

Tenure

CN¥1,445,000

Compensation

Dr. Jianying Wu has been General Manager and Executive Director of Shanghai Haohai Biological Technology Co., Ltd. since July 23, 2010. Mr. Wu worked as a surgeon at the General Surgery Department of the S ...


CEO Compensation Analysis

Compensation vs Market: Jianying's total compensation ($USD204.54K) is below average for companies of similar size in the German market ($USD1.55M).

Compensation vs Earnings: Jianying's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Yongtai Hou
Chairman9.75yrsCN¥1.17m3.37% CN¥51.5m
Jianying Wu
GM & Executive Director9.75yrsCN¥1.45m3.37% CN¥51.5m
Minjie Tang
CFO & Executive Director3.17yrsCN¥1.17m0.0039% CN¥60.1k
Yiyi Chen
Executive Director9.75yrsCN¥920.00k0.22% CN¥3.4m
Caixia Ren
Deputy General Manager9.75yrsno datano data
Wenbin Wang
Deputy General Manager1.08yrsno datano data
Jundong Zhang
Deputy General Manager1.08yrsno datano data
Weidong Tao
Deputy General Managerno datano data1.12% CN¥17.2m
Ming King Chiu
Joint Company Secretary5.42yrsno datano data
Min Tian
Board Secretary & Joint Company Secretary0.25yrno datano data

5.4yrs

Average Tenure

48.5yo

Average Age

Experienced Management: 5HB's management team is seasoned and experienced (5.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Yongtai Hou
Chairman9.75yrsCN¥1.17m3.37% CN¥51.5m
Jianying Wu
GM & Executive Director9.75yrsCN¥1.45m3.37% CN¥51.5m
Minjie Tang
CFO & Executive Director3.17yrsCN¥1.17m0.0039% CN¥60.1k
Yiyi Chen
Executive Director9.75yrsCN¥920.00k0.22% CN¥3.4m
Hongbo Shen
Independent Non-Executive Director5.5yrsCN¥84.00kno data
Jie You
Non Executive Director9.75yrsno data41.19% CN¥628.4m
Ming Ping Huang
Non-Executive Director9.75yrsCN¥825.00k1.12% CN¥17.2m
Yuanzhong Liu
Chairman of the Supervisory Committee9.75yrsno data1.12% CN¥17.2m
Huabin Chen
Independent Non-Executive Director5.5yrsCN¥84.00kno data
Qin Zhu
Independent Non-Executive Director5.5yrsCN¥84.00kno data

9.8yrs

Average Tenure

50.5yo

Average Age

Experienced Board: 5HB's board of directors are considered experienced (9.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.1%.


Top Shareholders

Company Information

Shanghai Haohai Biological Technology Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Shanghai Haohai Biological Technology Co., Ltd.
  • Ticker: 5HB
  • Exchange: DB
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$12.934b
  • Listing Market Cap: HK$1.526b
  • Shares outstanding: 177.83m
  • Website: https://www.3healthcare.com

Number of Employees


Location

  • Shanghai Haohai Biological Technology Co., Ltd.
  • WenGuang Plaza
  • 23rd Floor
  • Shanghai
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
6826SEHK (The Stock Exchange of Hong Kong Ltd.)YesForeign Shares-Foreign ListedHKHKDApr 2015
5HBDB (Deutsche Boerse AG)YesForeign Shares-Foreign ListedDEEURApr 2015
688366SHSE (Shanghai Stock Exchange)Domestic SharesCNCNYOct 2019

Biography

Shanghai Haohai Biological Technology Co., Ltd. engages in the research and development, manufacture, and sale of biomedical materials in Mainland China, the United States, the United Kingdom, and internationally. The company offers orthopedics, medical aesthetics and wound care; ophthalmology, and anti-adhesion and hemostasis products. It also provides medical sodium hyaluronate, medical chitosan, medical collagen sponge, and rhEGF, as well as biological reagents and materials. In addition, the company engages in the manufacture and sale of contact lens and intraocular lens materials, machines, and accessories; and investment and trading businesses. Further, it is involved in research and development of biological engineering and pharmaceutical products, related technology transfer, and consultation and service activities. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/09 23:36
End of Day Share Price2020/04/09 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.